Abstract:Cholangiocarcinoma (CCA) is a malignant tumor that arises within the biliary system, which exhibits a progressively increasing incidence and a poor patient prognosis. A thorough understanding of the molecular pathogenesis that drives the progression of CCA is essential for the development of effective molecular target therapeutic approaches. Ferroptosis is driven by excessive iron accumulation and catalysis, lipid peroxidation and the failure of antioxidant defense systems. Key molecular targets of iron metabolism, lipid metabolism and antioxidant defense systems involve molecules such as transferrin receptor, ACSL4 and GPX4, respectively. Inhibitors of ferroptosis include ferrostatin‐1, liproxstatin‐1, vitamin E and coenzyme Q10. By contrast, compounds such as erastin, RSL3 and FIN56 have been identified as inducers of ferroptosis. Ferroptosis serves a notable role in the onset and progression of CCA. CCA cells exhibit high sensitivity to ferroptosis and aberrant iron metabolism in these cells increases oxidative stress and iron accumulation. The induction of ferroptosis markedly reduces the ability of CCA cells to proliferate and migrate. Certain ferroptosis agonists, such as RSL3 and erastin, cause lipid peroxide build up and GPX4 inhibition to induce ferroptosis in CCA cells. Current serological markers, such as CA‐199, have low specificity and cause difficulties in the diagnosis of CCA. However, novel techniques, such as non‐invasive liquid biopsy and assays for oxidative stress markers and double‐cortin‐like kinase 1, could improve diagnostic accuracy. CCA is primarily treated with surgery and chemotherapy. A close association between the progression of CCA with ferroptosis mechanisms and related regulatory pathways has been demonstrated. Therefore, it could be suggested that multi‐targeted therapeutic approaches, such as ferroptosis inducers, iron chelating agents and novel modulators such as YL‐939, may improve treatment efficacy. Iron death‐related genes, such as GPX4, that are highly expressed in CCA and are associated with a poor prognosis for patients may represent potential prognostic markers for CCA. The present review focused on molecular targets such as p53 and ACSL4, the process of targeted medications in combination with PDT in CCA and the pathways of lipid peroxidation, the Xc‐system and GSH‐GPX4 in ferroptosis. The present review thus offered novel perspectives to improve the current understanding of CCA.

Implication of Ferroptosis in Cholangiocarcinoma: A Potential Future Target?

Emerging insights into ferroptosis in cholangiocarcinoma (Review)

Targeting Ferroptosis in Breast Cancer

Ferroptosis in hepatocellular carcinoma, from mechanism to effect

Ferroptosis: insight into the treatment of hepatocellular carcinoma

Ferroptosis: a New Promising Target for Hepatocellular Carcinoma Therapy

Current Progress of Ferroptosis Study in Hepatocellular Carcinoma

Ferroptosis: a new hunter of hepatocellular carcinoma

Ferroptosis in hepatocellular carcinoma: from bench to bedside

The Emerging Role of Ferroptosis in Liver Cancers

Ferroptosis-mediated Crosstalk in the Tumor Microenvironment Implicated in Cancer Progression and Therapy

Ferroptosis in Non-Small Cell Lung Cancer: Progression and Therapeutic Potential on It

Ferroptosis as a potential target for cancer therapy

Ferroptosis in Hepatocellular Carcinoma: Mechanisms and Targeted Therapy

Targeting Ferroptosis in Colorectal Cancer

Ferroptosis: the balance between death and survival in colorectal cancer

Ferroptosis in cancer immunity and immunotherapy: Multifaceted interplay and clinical implications

Targeting ferroptosis-elicited inflammation suppresses hepatocellular carcinoma metastasis and enhances sorafenib efficacy

Ferroptosis and its emerging role in tumor

Molecular mechanism of ferroptosis and its application in the treatment of clear cell renal cell carcinoma

Ferroptosis is an effective strategy for cancer therapy